An observational study in Anterior Blepharitis, sponsored by Brent Kramer. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Brent Kramer · Observational
The goal of this observational study is to determine the presence and prevalence of fungal organisms in four distinct blepharitis populations.
73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.
Browse Blepharitis studies →Brent Kramer is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A total of 60 eyes from 60 subjects will be included in the study. Per group: 15 eyes from 15 subjects (continue run-in enrollment until 15 subjects per group have been reached) enrolled from approximately 6 sites around the US.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No recent blepharitis treatment for previous 6 months, including warm compresses or lid scrubs; no history of seborrheic dermatitis (excluding seborrheic blepharitis)
Subjects grouped into this arm may be treatment-naïve or have received previous treatment for blepharitis (including warm compresses or lid scrubs). Investigators will capture these details at screening to further elicit the etiology of potential fungal blepharitis.
Completed Xdemvy ≥4 weeks prior; persistent symptoms. No history of seborrheic Dermatitis, excluding seborrheic blepharitis.
History of topical antibiotic with or without steroid therapy for the treatment of blepharitis in the last 6 months; persistent symptoms. No history of seborrheic dermatitis, excluding seborrheic blepharitis.
Percentage of subjects in each group with laboratory-confirmed fungal organisms
Reported as % positive per group
Time frame: Day -14 or Greater
Comparison of fungal prevalence
* Collarette-positive vs collarette-negative subjects (across all cohorts) * History of seborrheic dermatitis vs no history as well as sub-groups * Pre- vs post-Xdemvy (lotilaner ophthalmic solution) * Post antibiotic/steroid vs treatment-naïve * Fungal burden (semi-quantitative) * Organism type (yeast vs filamentous fungi) * Correlation with clinical signs: Erythema, Scaling, Madarosis
Time frame: Day -14 or Greater
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brent Kramer